$ICUI

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

ICU Medical reported Q3 2026 revenue of $560.4M, beating estimates by 1.5%, with adjusted EPS of $2.44, a 13.6% beat. Adjusted EBITDA was $113.9M, a 7% beat. Management reiterated full-year adjusted EPS guidance of $8.80 and EBITDA guidance of $425M. Operating and free cash flow margins improved significantly year-over-year.

ICU MEDICAL INC/DE (ICUI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture a

Shares of iRhythm, ICU Medical, Globus Medical, Enovis, and CONMED surged 8%-16% after Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing. Analysts expect the biopharmaceutical sector to recover, with existing Medicare policies remaining intact. Enovis, down 7.9% YTD, is trading 22.5% below its 52-week high.

ICU Medical (ICUI) is set to report Q3 earnings, with analysts expecting 3.5% revenue growth. Last quarter, it beat revenue and EPS estimates, reporting $547.9M in revenue. Peers Merit Medical and Intuitive Surgical also beat expectations but saw stock declines. ICU Medical's stock is unchanged in the last month, with an average price target of $193.38.

Merit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.

Otsuka ICU Medical recalled a saline lot that may contain potassium chloride bags, marking the third such issue in 19 months. The FDA posted the recall, which affects 0.9% Sodium Chloride Injection, USP, 100 mL, lot 1042188. No injuries have been reported. The company has not linked the incidents, which involve the same product line.

ICU Medical Inc's (ICUI) VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69 each, totaling $819,000. She has sold 8,233 shares in the past year with no purchases. The company's stock has a P/E ratio of 140.92, higher than industry and historical averages. GuruFocus values the stock at $120.76, suggesting it is significantly overvalued.

ICU Medical's VP and General Counsel, Virginia Ruth Sanzone, sold 4,856 shares of common stock on September 3, 2026, under a Rule 10b5-1 trading plan adopted in June 2026. The sales occurred in four transactions at weighted average prices ranging from $167.67 to $171.52 per share, totaling approximately $819,000.

Sanzone Virginia Ruth (VP, General Counsel) sold 4,856 shares of ICU MEDICAL INC/DE (ICUI) at an average of $168.69 ($167.67–$171.52, $0.82M total) across 4 trades on 2026-09-03 under a Rule 10b5-1 trading plan.